Remove 2024 Remove Inventor Remove Litigation Remove Patent
article thumbnail

District Court Grants Summary Judgment and Invalidates Patent in REGENXBIO v. Sarepta Litigation

LexBlog IP

On January 5, 2024, in litigation between REGENXBIO and Sarepta Therapeutics, Judge Richard Andrews of the U.S. 10,526,617 (the ’617 Patent; licensed to REGENXBIO) is invalid as being directed to ineligible subject matter. A trial was scheduled to begin on January 29, 2024. last year is ongoing. § 101.

article thumbnail

…And The Covaxin Patent Saga Continues: BBIL Changes the Patent Application Again

SpicyIP

The Story Till Now On one hand, COVID-19 cases are rising yet again to everyone’s surprise, and on the other, the surprises from the Covaxin patent application don’t seem to stop. Two revisions in the patent applications have occurred since then, and this post analyses the events and their implications on the Covaxin patent.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Who Invented This? The Continuing Importance of Human Ingenuity in Patenting AI Related Inventions

IP Tech Blog

The Guidance clarifies that AI-assisted inventions can receive patent protection if a human being plays a significant role in the invention’s conception. The Guidance acknowledges the importance of human inventors in AI-assisted inventions, so that the patent system can continue to incentivize and reward human ingenuity.

article thumbnail

IP CloseUp will Exceed 400,000 Views in 2024; Last Year’s Top Posts Include S&P 500 Assets, Leading Black Inventors and Wiper Blade Invention Saga

IP Close Up

IP CloseUp, weekly perspective on intellectual property trends and business, broke through 392,000 views and 272,000 visits in 2023, on its way to 400,000 plus Continue reading

article thumbnail

False patent marking claims survive even when Dastar bars false advertising claims based on "innovation"

43(B)log

2024 WL 629985, No. 30, 2024) (R&R) Recommendation: Dastar should block Qingdao’s Lanham Act false advertising counterclaims based on Lashify’s claim to be the originator of lash technology, but false patent marking counterclaims should survive. 11, 2023 (claiming that various products were “patented”). patent law.

article thumbnail

USPTO Releases Inventorship Guidance for AI-assisted Inventions

LexBlog IP

The USPTO released inventorship guidance on February 12, 2024, for inventions assisted by artificial intelligence (AI). The Federal Circuit previously held that an AI system cannot be listed as an inventor in Thaler v. Vidal , 43 F.4th 4th 1207 (Fed. Iolab Corp. , 3d 1344 (Fed.

article thumbnail

Gilead and ViiV Healthcare Settle Global Patent Dispute for Over $1B USD

IPilogue

Patent 8,129,385 (“patent 385”). ViiV alleges Gilead infringed upon patent 385 under the doctrine of equivalents, which has two exclusions: dedication-disclosure and specific exclusion. The doctrine of equivalents prevents parties from circumventing literal infringement by making minor variations to a patented invention.

Patent 120